Fetal methylmercury syndrome

Fetal methylmercury syndrome, also known as prenatal methylmercury poisoning or congenital Minamata disease, is a condition caused by in utero exposure to methylmercury, a highly toxic organomercurial compound. This is not a genetic disorder but rather a teratogenic condition resulting from maternal consumption of methylmercury-contaminated food (most commonly fish or grain treated with mercury-containing fungicides) during pregnancy. Methylmercury readily crosses the placental barrier and the developing fetal blood-brain barrier, causing severe damage to the central nervous system. The syndrome primarily affects the brain and nervous system, leading to microcephaly, intellectual disability, cerebral palsy-like motor dysfunction, seizures, and severe developmental delay. Additional features may include visual impairment (including blindness), hearing loss, abnormal reflexes, impaired coordination (ataxia), and dysarthria. Some affected children may also exhibit growth restriction and feeding difficulties. The severity of the condition depends on the timing and degree of mercury exposure during pregnancy. There is no cure or specific treatment for fetal methylmercury syndrome. Management is supportive and symptomatic, focusing on rehabilitation therapies including physical therapy, occupational therapy, speech therapy, and special education services. Seizures are managed with anticonvulsant medications. Prevention through avoidance of methylmercury exposure during pregnancy remains the most important public health measure. The condition was first widely recognized following mass poisoning events in Minamata Bay, Japan (1950s-1960s) and in Iraq (1971-1972).

Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Common questions about Fetal methylmercury syndrome